Nathasha Rizza1, Gary Pitcairn1,2, Jakob Samsøe1 & Jerker Carlsson1
1Iconovo AB, Ideongatan 3A-B, Lund, 22370, Sweden
2GRP Consulting AB, Mölndal, Sweden
Summary
Drug delivery from a novel, single dose passive nasal DPI (ICOone®) was assessed using two model spray dried powder formulations. The emitted dose (ED) and regional drug deposition in the Alberta Idealised Nasal Inlet (AINI) was assessed at 4 different inhaled flow rates (15, 20, 30 and 45 L/min). For both formulations, the mean emitted dose was 84% or greater across the flow rates tested with a trend towards higher values at higher flow rates.
Regional drug deposition from the ICOone® device was consistent across the flow rates tested; for both formulations the dose was deposited predominantly in vestibule and turbinate regions, with very little deposition occurring in the olfactory and nasopharynx regions or filter. The deposition data showed that drug delivery to the vestibule and turbinates was relatively flow rate independent for both formulations. Overall, it was concluded that drug delivery from the ICOone® was robust for the formulations assessed, indicating that the device may be suitable for use in clinical development programs.